(Image source from: Canva.com)
Japan has granted approval for innovative stem-cell therapies aimed at treating Parkinson's disease and severe heart failure, according to reports from the company and news sources on Friday. These treatments are anticipated to be accessible to patients within a few months. The pharmaceutical firm Sumitomo Pharma announced that it has been authorized to produce and sell Amchepry, which is designed to transplant stem cells into the brain of individuals with Parkinson's disease. Additionally, the country's health ministry has authorized ReHeart, a development of the medical startup Cuorips, which creates heart muscle sheets that can aid in the formation of new blood vessels and restore heart function, according to media outlets. Reports have indicated that these therapies might be available for patients as soon as this summer, potentially becoming the first commercially sold medical products utilizing induced pluripotent stem (iPS) cells. Japanese researcher Shinya Yamanaka earned a Nobel Prize in 2012 for his work on iPS cells, which can change into any type of cell in the human body. Health minister Kenichiro Ueno expressed hope that these advancements will benefit not just patients in Japan but worldwide during a press meeting.
“We will quickly complete all essential steps to make sure it reaches every patient as planned. ”
In a statement, Sumitomo Pharma mentioned that it received "temporary and restricted approval" for the production and sale of Amchepry through a system aimed at speeding up the process of bringing these products to patients. This approval is mentioned to be a type of "temporary license," as reported by the Asahi newspaper, after assessing the treatment's safety and effectiveness based on data from a smaller number of patients than is typical for regular drug trials. A study led by researchers from Kyoto University suggested that the treatment is both safe and effective in alleviating symptoms. The trial involved seven patients with Parkinson's, aged 50 to 69, who received either five million or ten million cells implanted into each side of their brains.
The iPS cells, harvested from healthy donors, were developed into precursor cells for dopamine-producing neurons, which are absent in those with Parkinson's disease. The patients were observed for a period of two years, during which no significant side effects were reported, according to the study. Four patients experienced improvements in their symptoms. Parkinson's disease is a long-lasting, progressive neurological condition that impacts the motor system, often leading to tremors and other movement challenges. The Parkinson's Foundation estimates that around 10 million individuals worldwide are affected by this condition. The current treatments available "alleviate symptoms but do not slow down or stop the progression of the disease," as stated by the foundation. iPS cells are generated by reversing mature, specialized cells back to a younger state, essentially cloning without using an embryo. These cells can be converted into various types of cells, making their application a crucial area of medical research.
